Diagnostic value of D2-40 immunostaining for malignant mesothelioma: a meta-analysis
Metrics: PDF 1321 views | HTML 2263 views | ?
Chao He1,*, Bo Wang2,*, Chun Wan3, Ting Yang3 and Yongchun Shen3
1Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu 610041, China
2Intensive Care Unit, West China Hospital of Sichuan University, Chengdu 610041, China
3Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu 610041, China
*These authors have contributed equally to this work
Yongchun Shen, email: [email protected]
Keywords: malignant mesothelioma, D2-40, diagnosis, meta-analysis
Received: March 10, 2017 Accepted: June 18, 2017 Published: July 06, 2017
Malignant mesothelioma (MM) has become a global disease burden for its rising incidence and invariable fatality. D2-40 has been widely used as an immunostaining marker of diagnosing MM, while its diagnostic value has not yet been evaluated. Our study aimed to assess the overall accuracy of D2-40 immunostaining for diagnosing MM through a meta-analysis. A total of 22 studies with 2,264 participants were identified from PubMed, EMBASE, Web of Science, Scopus and the Cochrane database. The pooled sensitivity and specificity of D2-40 for MM was 0.86 (95% CI: 0.84–0.89) and 0.77 (95% CI: 0.74–0.79), respectively. The area under the summary receiver operating characteristic curve is 0.93, with a diagnostic odds ratio 40.37 (95% CI: 19.97–81.61). None of the study variates was found to be a source of heterogeneity after meta-regression analysis. In conclusion, D2-40 immunostaining may not give sufficient evidence by itself to diagnose MM and should be in combination with other markers to improve the accuracy of diagnosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.